Reasons for not experiencing weight loss on Tirzepatide can include individual metabolic differences, improper dosage, or counteracting lifestyle habits
While most digestive side effects of tirzepatide are manageable and self-limiting, certain symptoms warrant prompt medical evaluation
Lixisenatide demonstrated a stronger association with hypoglycemia compared to other GLP-1RAs, according to the highest reporting odds ratio (ROR) (28.03, 95% confidence interval =15.92, 49.32), empirical Bayes geometric mean [26.00, 95% confidence interval (CI): 16.20], and proportional reporting ratio (PRR) (26.01, 2 =313.37)
Glycemic improvements typically become apparent within 4 weeks of reaching therapeutic doses (5 mg or higher), with maximal HbA1c reduction at 12-24 weeks